The Novavax vaccine would be the first protein-based alternative available in Israel
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company based in Gaithersburg dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Israel’s Ministry of Health today announced an agreement for the purchase of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.